Tirzepatide · dosing reference

What dose information exists for Tirzepatide?

An approved dual GIP/GLP-1 receptor agonist with authoritative prescribing labels. Compounded or research-grade copies are chemically distinct and lack FDA safety verification.

Official product dosing

Official

Approved indication, route, dose, frequency and titration, sourced only from the FDA label, DailyMed or the manufacturer's prescribing information.

Official labelMOUNJARO / ZEPBOUND (tirzepatide) injection

Approved indication: Type 2 diabetes mellitus (Mounjaro); chronic weight management in adults with obesity or overweight with comorbidities (Zepbound).
Route: Subcutaneous injection once weekly
Dose: Initiate at 2.5 mg once weekly for 4 weeks; escalate to 5 mg once weekly. If needed, increase by 2.5 mg increments every 4 weeks to 7.5 mg, 10 mg, 12.5 mg, up to maximum 15 mg weekly.
Frequency: Once weekly
Titration: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → optional escalations in 2.5 mg steps every 4 weeks up to 15 mg.

The 2.5 mg dose is intended for treatment initiation and is not effective for glycemic control or weight management on its own.

Published human study doses

Human study

Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.

Human studyJastreboff et al., NEJM (2022) — SURMOUNT-1

Population: 2,539 adults with obesity or overweight without diabetes
Route: Subcutaneous
Dose as published: Once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg for 72 weeks
Frequency: Once weekly
Duration: 72 weeks
Endpoint: Mean percentage change in weight at week 72: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% (placebo).

Why community reports are shown at all

People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.

Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built